Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound bone scan takes on x-ray standard for spotting osteoporosis

NCT ID NCT07876882

Diagnosis Sponsor: BoneVue Diagnostics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 15, 2026 · Last updated Oct 16, 2026 · Updated 1 time

Summary

Researchers are testing whether a radiation-free ultrasound method called REMS can diagnose osteoporosis and predict fracture risk as well as the standard DXA X-ray scan. About 250 men and women aged 30 to 90 who are having their bone health checked will receive both scans. The study compares how often the two methods agree and follows participants by phone for a year to see which method better predicts broken bones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiofrequency echographic multi spectrometry (REMS), an ultrasound-based bone scanning method
What this could lead to
If REMS matches DXA, it could offer a radiation-free, portable way to screen for osteoporosis and estimate fracture risk.
What could go wrong
This is an observational comparison at a single practice, so results may not hold in other settings. REMS may miss cases that DXA catches, and the 12-month follow-up is short for predicting fractures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of male and female U.S. subjects aged 30 to 90 years who are at risk for osteoporosis and present to Rheumatology Associates of Delmarva for evaluation of bone health or osteoporosis risk. Eligible participants must have undergone a clinically ordered DXA scan of the lumbar spine and proximal femur within the 7 days preceding the REMS examination, be able to provide written informed consent, and be able to comply with study procedures, including telephone follow-up at 6 and 12 months. The study plans to enroll approximately 250 participants with evaluable paired REMS and DXA data.

Ages

30 to 90 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 30-90 years at time of enrollment * Presenting for evaluation of bone health or osteoporosis risk assessment * Has undergone a clinically ordered DXA scan (lumbar spine, proximal femur) as part of routine medical care through the subject's healthcare provider within the seven days immediately preceding the REMS examination * Willing and able to provide written informed consent * Able to comply with study procedures, including telephone follow-up interviews at 6- and 12-months post-enrollment Exclusion Criteria: * Inability to provide written informed consent * Inability to complete an adequate REMS examination * Declared pregnancy as collected per standard of care prior to DXA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone health are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone fracture osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone health Fracture Osteoporosis diagnosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rheumatology Associates of Delmarva

    RECRUITING

    Easton, Maryland, 21601, United States

  • Rheumatology Associates of Delmarva

    RECRUITING

    Salisbury, Maryland, 21804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.